UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000030917 |
|---|---|
| Receipt number | R000035302 |
| Scientific Title | The Assessment of Preoperative Diagnostic Accuracy of Multidetector-row computed tomography (MDCT) for Resectable Biliary Cancer |
| Date of disclosure of the study information | 2018/02/15 |
| Last modified on | 2019/07/24 09:29:57 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
The Assessment of Preoperative Diagnostic Accuracy of Multidetector-row computed tomography (MDCT) for Resectable Biliary Cancer
Acronym
The Assessment of Preoperative Diagnostic Accuracy of Multidetector-row computed tomography (MDCT) for Resectable Biliary Cancer (Pre-BICA)
Scientific Title
The Assessment of Preoperative Diagnostic Accuracy of Multidetector-row computed tomography (MDCT) for Resectable Biliary Cancer
Scientific Title:Acronym
The Assessment of Preoperative Diagnostic Accuracy of Multidetector-row computed tomography (MDCT) for Resectable Biliary Cancer (Pre-BICA)
Region
| Japan |
Condition
Condition
Biliary cancer
Classification by specialty
| Hepato-biliary-pancreatic surgery |
Classification by malignancy
Malignancy
Genomic information
NO
Objectives
Narrative objectives1
To validate the accuracy of MDCT diagnosis of the pathological TNM stage of biliary cancer, that fulfills the inclusion criteria of the future phase III trial (preoperative therapy + surgery vs. surgery alone) planned in HBP group of Japan Clinically Oncology Group (JCOG)
Basic objectives2
Others
Basic objectives -Others
Validation study
Trial characteristics_1
Others
Trial characteristics_2
Others
Developmental phase
Not applicable
Assessment
Primary outcomes
The proportion of pathological stage I (stage IA in distal bile duct cancer) among the patients who were diagnosed with a biliary cancer that fulfills the inclusion criteria of preoperative therapy trial on MDCT
Key secondary outcomes
Sensitivity and specificity of MDCT to diagnose a biliary cancer that fulfills the inclusion criteria of preoperative therapy trial; Sensitivity and specificity of MDCT to diagnose the lymph node metastasis; Sensitivity and specificity of MDCT to diagnose the R1 (invasive cancer) or R2 resection
Base
Study type
Observational
Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| Not applicable |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
Patients who fulfills all the following inclusion criteria
1) The patient is diagnosed with adenocarcinoma of biliary tract by pathological examination of resected or pre-/intra- operative biopsied specimen (The pathological diagnosis is conducted according to the sixth edition of General Rules for the Clinical and Pathological Study of Primary Liver Cancer in intrahepatic bile duct cancer, and according to the sixth edition of Classification of Biliary Tract Cancers in other biliary cancers)
2) The patients who underwent the contrast-enhanced multidetector-row computed tomography (MDCT) examination (5mm or less slice, regardless the presence or absence of biliary drainage) within 60 days before operation, and were diagnosed with resectable biliary cancer (without distant metastasis and R0/1 resection possible)
3) The patients underwent laparotomy with the intent of tumor resection between 2014 and 2016 in the institution of JCOG (including not only the resected cases but also the unresected cases)
4) The patients do not have a past history of either preoperative chemotherapy or radiation therapy in the upper abdomen
Key exclusion criteria
1) The patients with intrahepatic bile duct cancer with the macroscopic appearance of periductal infiltrating type, intraductal-growth type or predominant type of either, because General Rules for the Clinical and Pathological Study of Primary Liver Cancer is not applied to these types.
2) The patients who underwent preoperative image examination only in other hospital
3) The patents who have other active cancers at the time of operation
Target sample size
1000
Research contact person
Name of lead principal investigator
| 1st name | Kazuaki |
| Middle name | |
| Last name | Shimada |
Organization
National Cancer Center Hospital
Division name
Hepatobiliary and Pancreatic Surgery Division
Zip code
104-0045
Address
5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045 Japan
TEL
03-3542-2511
kshimada@ncc.go.jp
Public contact
Name of contact person
| 1st name | Satoshi |
| Middle name | |
| Last name | Nara |
Organization
National Cancer Center Hospital
Division name
Hepatobiliary and Pancreatic Surgery Division
Zip code
104-0045
Address
5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045 Japan
TEL
03-3542-2511
Homepage URL
sanara@ncc.go.jp
Sponsor or person
Institute
The Hepatobiliary and Pancreatic Oncology (HBPO) Group of the Japan Clinical Oncology Group (JCOG)
Institute
Department
Personal name
Funding Source
Organization
Japan Agency for Medical Research and Development
Organization
Division
Category of Funding Organization
Other
Nationality of Funding Organization
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Institutional review board of National Cancer Center Hospital
Address
5-1-1, Tsukiji, Chuo-ku, Tokyo, 104-0045 Japan
Tel
03-3542-2511
NCC_IRBoffice@ml.res.ncc.go.jp
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
札幌厚生病院（北海道）
北海道大学病院（北海道）
手稲渓仁会病院（北海道）
東北大学病院（宮城県）
栃木県立がんセンター（栃木県）
自治医科大学（栃木県）
埼玉県立がんセンター（埼玉県）
国立がん研究センター東病院（千葉県）
千葉大学医学部（千葉県）
国立がん研究センター中央病院（東京都）
神奈川県立病院機構神奈川県立がんセンター（神奈川県）
横浜市立大学附属市民総合医療センター（神奈川県）
新潟県立がんセンター新潟病院（新潟県）
富山大学附属病院（富山県）
金沢大学医学部（石川県）
静岡県立静岡がんセンター（静岡県）
大阪国際がんセンター（大阪府）
国立病院機構大阪医療センター（大阪府）
関西医科大学附属病院（大阪府）
兵庫医科大学（兵庫県）
兵庫県立がんセンター（兵庫県）
山口大学医学部附属病院（山口県）
国立病院機構四国がんセンター（愛媛県）
国立病院機構九州がんセンター（福岡県）
Other administrative information
Date of disclosure of the study information
| 2018 | Year | 02 | Month | 15 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
1237
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
Completed
Date of protocol fixation
| 2017 | Year | 11 | Month | 30 | Day |
Date of IRB
| 2017 | Year | 12 | Month | 14 | Day |
Anticipated trial start date
| 2017 | Year | 12 | Month | 26 | Day |
Last follow-up date
| 2018 | Year | 06 | Month | 30 | Day |
Date of closure to data entry
Date trial data considered complete
Date analysis concluded
Other
Other related information
This study is a multi-institutional retrospective observational study
Management information
Registered date
| 2018 | Year | 01 | Month | 21 | Day |
Last modified on
| 2019 | Year | 07 | Month | 24 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000035302
